Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low-to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent MDS stem cells (MDS-SCs), and their hierarchical relationship to lineage-restricted MDS progenitors. All identified somatically acquired genetic lesions were backtracked to distinct MDS-SCs, establishing their distinct MDSpropagating function in vivo. In isolated del(5q)-MDS, acquisition of del(5q) preceded diverse recurrent driver mutations. Sequential analysis in del(5q)-MDS revealed genetic evolution in MDS-SCs and MDS-progenitors prior to leukemic transformation. These findings provide definitive evidence for rare human MDS-SCs in vivo, with extensive implications for the targeting of the cells required and sufficient for MDS-propagation.
INTRODUCTION
The concept that human cancers might be propagated exclusively by rare self-renewing cancer stem cells (CSCs), replenishing nontumorigenic cancer cells, has extensive implications for the development of targeted cancer therapies (Clevers, 2011; Magee et al., 2012) . Whereas the existence of cells with human CSC-potential has been supported experimentally in some hematological malignancies (Bonnet and Dick, 1997; Goardon et al., 2011; Jamieson et al., 2004; Nilsson et al., 2000) and solid tumors (Al-Hajj et al., 2003; Schatton et al., 2008) , the CSC concept has recently been contested in mouse and man (reviewed in Clevers, 2011; Magee et al., 2012) through multiple studies suggesting that cells with CSC potential, including leukemic stem cells (LSCs), might be neither rare (Kelly et al., 2007; Quintana et al., 2008) nor phenotypically or molecularly distinct (le Viseur et al., 2008; Quintana et al., 2008) . Of particular relevance, compelling evidence has demonstrated significant, intrinsic limitations of existing human CSC and LSC in vivo assays (Clevers, 2011; Kelly et al., 2007; Magee et al., 2012; Taussig et al., 2008) , failing to reveal the cancer-propagating potential of investigated cancer cell populations as illustrated by a large fraction of patients with acute myeloid leukemia (AML) having no leukemic cells reading out in LSC assays (Pearce et al., 2006) . Regardless, in vitro or in vivo CSC/LSC assays cannot establish to what degree different cancer cells act to propagate the cancer in patients, which ultimately is the most biologically and clinically relevant CSC property. Proposed identities of human CSCs/LSCs therefore await definitive verifications in patients (Clevers, 2011; Magee et al., 2012) , although it will be difficult to apply the genetically engineered lineage-tracing technologies in human malignancies, which recently allowed the definitive identification and fate-mapping of mouse CSCs in vivo Driessens et al., 2012; Schepers et al., 2012) .
Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by inefficient hematopoiesis and frequent progression to AML (Nimer, 2008) . Even in low-risk MDS, clonal hematopoiesis already dominates at diagnosis, and clones found in secondary AML originate from the MDS stage of disease (Walter et al., 2012) , highlighting the need to specifically target the MDS-initiating clone. Previous studies provided support for del(5q)-MDS originating in hematopoietic stem cells (HSCs; Nilsson et al., 2000) , and in vitro and in vivo stem cell (SC) assays have supported that rare CD34 + CD38 À cells possess MDS-SC potential in low-to intermediate-risk MDS (Nilsson et al., 2000 (Nilsson et al., , 2002 Pang et al., 2013; Tehranchi et al., 2010) . However, it remains to be established whether CD34 + CD38 À cells are the only cells with SC potential in MDS because other MDS progenitors, including distinct myeloid progenitor subsets (Manz et al., 2002) , have yet to be explored for their MDS-SC potential (Agarwal, 2012; ASH-Workshop, 2010; Nilsson et al., 2000; Pang et al., 2013) . This is particularly relevant because genomic lesions might potentially confer in vivo selfrenewal ability to otherwise short-lived myeloid progenitors. We hypothesized that recently identified recurrent somatic driver-mutations in low-to intermediate-risk MDS (Bejar et al., 2011; Papaemmanuil et al., 2011 Papaemmanuil et al., , 2013 Yoshida et al., 2011) should provide genetic tools to map the identity and fate of MDS-propagating cells in patients in vivo.
RESULTS

Conservation of a Hierarchy of Molecularly and Functionally Distinct Stem and Progenitor Cells in Lowto Intermediate-Risk MDS
Because candidate CSCs/LSCs have frequently not been documented to be molecularly and functionally distinct or hierarchically related to other cancer/leukemic cells (Clevers, 2011; le Viseur et al., 2008; Magee et al., 2012) , a requirement for our fate mapping approach to be informative, we first compared the phenotypic, molecular and functional properties as well as hierarchical relationships of Lineage À (Lin
À candidate MDS-SCs with myeloid-restricted granulocyte-macrophage and megakaryocyte-erythroid progenitors (GMPs and MEPs, respectively; Majeti et al., 2007; Manz et al., 2002) . In all investigated MDS cases (Table S1 available online) , phenotypically defined SCs, GMPs, MEPs, and common myeloid progenitors (CMPs) were identified in agreement with previous studies (Pang et al., 2013; Will et al., 2012) . Each population was preserved at a low frequency despite high clonal involvement ( Figures 1A-1D ). Absolute numbers of phenotypic SCs and CMPs were expanded and GMPs reduced compared to age-matched controls in isolated del(5q) MDS, other patients with low-to intermediate-risk MDS with del(5q), and in nondel(5q) MDS ( Figure 1B ). As reported recently for patients with low-risk MDS (Pang et al., 2013) , the suppression of GMPs and increase in CMPs became clearer in del(5q) and nondel(5q) MDS cases when assessed relative to the whole Lin À
CD34
+ CD38 + progenitor compartment ( Figure 1B ). This analysis also revealed that MEPs were relatively suppressed in non-del(5q) cases, but not in cases with del(5q) ( Figure 1B Figures 1C and 1D ), suggesting that del(5q) MDS-SCs outcompete normal HSCs. With FISH, del(5q) was found to be high in CMPs, GMPs, MEPs, and SCs, although slightly lower in GMPs and MEPs as determined by sequencing ( Figure 1D ), suggesting perhaps a slight Figures 1E and 1F) , and importantly had myeloid-and erythroid-restricted lineage potentials, respectively, in vitro ( Figure 1G ; Figures S1A and S1B). MDS CMPs (Figure 1A) expressed, as normal CMPs, both lineage programs, which were low to absent in candidate MDS-SCs ( Figure S1C ). Genes characteristic of normal HSCs were selectively expressed in MDS Lin Figure 1H ). The distinct molecular signatures of MDS SCs, GMPs, and MEPs was further underpinned by a principle component analysis of RNA sequencing data from purified stem and progenitor cells ( Figure 1I ), demonstrating that SCs, GMPs, and MEPs from patients with MDS and age-matched normal controls clustered together and distant from the other cell populations. The ability to sustain long-term generation of MDS myeloid progenitors in vitro (Hogge et al., 1996) Figure 1J ; Figure S1D ). (Pearce et al., 2006) , it is not surprising that also in most cases of MDS the bone marrow (BM) cells fail to reconstitute immune-deficient mice (Nilsson et al., 2002; Thanopoulou et al., 2004) , although in a recent study SCs from a few monosomy 7 MDS cases did engraft (Pang et al., 2013 Figure 2E ; Figure S2D ). Not previously investigated (Pang et al., 2013) Figure 2E ; Figure S2D) Figure 2F ; Figure S2E ; Pang et al., 2013; Sternberg et al., 2005 Figure 2K ; Figure S2H ) Recent studies have highlighted the inability of established CSC assays to reliably identify tumor-propagating cells in patients (Clevers, 2011; Kelly et al., 2007; Magee et al., 2012; Quintana et al., 2008; Taussig et al., 2008) , including in MDS (Agarwal, 2012; ASH-Workshop, 2010 Figures 3B and 3C ).
Thus, we performed targeted screening for somatic DNA (B) Mean (SEM) stem/progenitor cell percentages in normal age-matched controls (n = 7) and low-to intermediate-risk isolated del(5q) (n = 9), del(5q) RCMD/ RAEB-1 (n = 11) and non-del(5q) (n = 12) MDS in total BM (top row), and Lin ) and progenitor cells from del(5q) MDS (n = 15) and non-del(5q) MDS (n = 11). See also Figure S1 and Table S1 . including those encoding transcription factors (RUNX1, ETV6), components of signaling pathways (JAK2, CSF3R), epigenetic regulators (TET2, ASXL1), apoptosis regulators (TP53), and spliceosome components (SF3B1, SRSF2, U2AF2, SRSF6). Importantly, these mutations were typically present in the dominant MDS clone as evidenced by a mean variant allele frequency (VAF) in whole BM cells of 30.8% (±3.3%; Figure 4B ; Table S2 ), demonstrating that they must indeed have originated in cells actively propagating the MDS clone in vivo, fulfilling the strictest definition of CSCs (Clevers, 2011; Magee et al., 2012) . All these genomic lesions were tracked back to the rare Lin See also Figure S3 and Table S2. but not restricted to, the distinct subgroup of MDS with isolated del(5q) (previously termed 5qÀ syndrome; Nimer, 2008) . While recent targeted sequencing studies of MDS patients (Bejar et al., 2011; Fernandez-Mercado et al., 2013; Papaemmanuil et al., 2013) and our data ( Figure 4A ) suggest that isolated del(5q) MDS cases frequently harbor additional driver mutations, the order of the mutation acquisition relative to del(5q) has not been examined in detail.
To explore this further, we utilized three independent data sets from low-to intermediate-risk MDS cases with del(5q): (1) inhouse targeted resequencing of 17 new cases; (2) computational analysis of 36 cases from a previous study (Papaemmanuil et al., 2013) , including assessment of the frequencies of cells with del(5q); and (3) nine cases with whole exome sequencing data (Tables S1 and S3 ). In 19 (36%) of the 53 targeted resequencing cases, no further recurrent driver mutations were identified, a pattern confirmed in five of the nine whole exome-sequenced cases ( Figure 5A ; Table S3 ). In 12 of the additional 16 cases with one or more recurrent driver mutations and in which computational analysis allowed high confidence prediction (18 cases did not; Figure S4A ), del(5q) was predicted to have occurred as the first genetic lesion, whereas in only four cases was a recurrent driver mutation predicted to have preceded del(5q) ( Figure 5B) . Notably, in all high-confidence cases where the diagnosis was isolated del(5q) (n = 18) or RAEB-1/RCMD (n = 10), del(5q) was predicted to be the first (or only) genetic lesion, regardless of the identity or number of recurrent driver mutations identified ( Figure 5C ).
Eighteen cases showed overlapping estimates of clonal fractions for both del(5q) and the acquired mutations ( Figure S4A ). To delineate these relationships, we performed single cell analysis in four of these cases, two isolated del(5q) and two RCMD/RAEB-1, and were able to provide evidence that del(5q) also preceded the identified driver mutations in each of these 
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Rare MDS-Propagating Cancer Stem Cells In Vivo cases ( Figure 5D ). In contrast, in all four cases in which del(5q) was predicted not to be the initiating genetic lesion, del(5q) was preceded by a recurrent mutation in SF3B1, and all of these patients had been diagnosed with RARS or RCMD-RS ( Figures 5B and 5C ). Recently, compelling evidence for the existence of TIM3 À pre-AML SCs was reported, defined as HSCs harboring some but not all recurrent driver mutations identified in the bulk AML, and contributing to balanced lympho-myeloid reconstitution in NSG mice (Jan et al., 2012) . Here, we observed no long-term B lymphoid reconstitution in NSG mice transplanted with CD34 + BM cells from nine MDS cases with del(5q) ( Figures S4B and  S4C ), similar to a recent study which also found exclusive long-term myeloid and no B cell contribution from HSCs purified from low-risk MDS patients (Pang et al., 2013 Figure S4E ). Thus, in agreement with our findings compatible with del(5q) being the initiating and potentially also the only required genetic lesion for development of isolated del(5q)-MDS, we found no evidence for pre-MDS SCs in low-to intermediate-risk MDS with del(5q). (Figures 6 and 7) . Two of the patients (patients 2 and 39) had stable disease, and exome-sequencing was performed at diagnosis as well as 30-32 months later when they remained transfusion-independent on long-term lenalidomide. At this time, the MDS-SCs, MEPs, and GMPs retained distinct phenotypic, functional, and molecular signatures (Figures 6A-6C ; Figure S5 ). Exome-sequencing identified no (patient 2) and two (patient 39; Figure 6D ) recurrent driver mutations, and in both cases a number of predicted somatic passenger mutations (Table S4) patients that all identified mutations had occurred in a linear manner ( Figure 6F , Table S5 ). Notably, neither of these two patients have transformed to AML in the 2-4 years since the last analysis.
Evolution of Genetic Lesions in del(5q) MDS Stem Cells during Disease Progression
In a third, isolated del(5q) case (patient 3) with distinct SC and progenitor signatures ( Figures 7A-7C, S6) , who transformed to AML only 13 months later (no AML sample available), exomesequencing of BM cells (23 months after diagnosis) obtained when the patient was responding well to lenalidomide, identified six somatic mutations, including a recurrent TP53 mutation, associated with poor prognosis (Jä dersten et al., 2011) . None of these could be confidently identified in bulk BM cells at diagnosis neither by exome ( Figure 7D ; Table S6 ) nor targeted (Table  S7) sequencing. However, all identified mutations could be backtracked to the MDS-SC compartment at 23 months (Figure 7E) , and individual LTC-CFC analysis confirmed that del(5q) along with a nonrecurrent MINA mutation preceded the other mutations, including the TP53 mutation ( Figures 7F, 7G , S3, and S6; Table S7) .
A fourth patient with isolated del(5q) was analyzed before and following lenalidomide treatment, as well as at disease progression preceding AML transformation (Figures 7H-7Q ; Figure S6 ; Table S1 ). Exome-sequencing identified 15 somatic mutations at disease progression, including a recurrent JAK2V617F and a recurrent TP53 mutation. The JAK2V617F and ten other nonrecurrent mutations were confidently identified in the bulk BM cells as well as in purified 7N ; Tables S6 and S7 ). The patient later lost lenalidomide responsiveness and progressed to higher risk MDS (RAEB-1; 9% BM blasts), at which time exome-sequencing identified three additional mutations (Figures 7K-7N ; Tables S6 and S7 Table S7 ). This suggested that the PIFO mutation might have occurred in a progenitor population outside the Colonies shown at the furthest right were analyzed for presence of recurrent driver mutations only. Each vertical column shows mutation status in an individual LTC-CFC. See also Figure S5 and Tables S4 and S5 . (Majeti et al., 2007) had expanded at the time of progression ( Figure 7H ), we also performed targeted resequencing of these progenitor populations ( Figures 7O and 7P) , and identified, at progression but not in the preceding sample, PIFO variant reads at similar high frequencies as for the TP53 mutation (Figures 7O  and 7P ; Table S7 ). These findings were compatible with the preceding recurrent TP53 mutation that occurred in the Lin 
CD38
À CD90 + SC compartment.
In further support of this, single cell analysis confirmed the mutually exclusive relationship of the IKZF1 (and SPRED2) and PIFO mutations, representing distinct del(5q) subclones, which prior to this branching had sequentially acquired recurrent del(5q), JAK2 V617F, and TP53 genetic lesions (Figures 7Q and 7R ; Table S7 ). Notably, this patient transformed to AML 7 months later (from which time no BM or blood sample was available).
DISCUSSION
Efforts to identify distinct human CSCs have become a major focus in translational and clinical cancer research. Consequently, it was a considerable setback, yet to be resolved, when many studies established the inability of in vivo CSC assays to reliably uncover the tumorigenic potential of many cancer cell populations, including in hematological malignancies (Clevers, 2011; Kelly et al., 2007; le Viseur et al., 2008; Magee et al., 2012; Pearce et al., 2006; Quintana et al., 2008; Taussig et al., 2008) . Moreover, the identification of distinct human CSCs exerting their potential in patients (Clevers, 2011; Magee et al., 2012) , including in MDS (Agarwal, 2012; ASH-Workshop, 2010) , has remained elusive. À CD90 + MDS-SCs provides evidence for the existence of rare human CSCs in vivo, and that these are the only MDS-SCs in vivo in low-risk MDS. This finding has wide clinical implications, highlighting that propagation and evolution of genetic lesions in the MDS clone is strictly dependent on a rare SC at early stages of MDS. In all investigated cases, the candidate driver mutations were all part of the same dominating SC clone, suggesting that they provide MDS-SCs with a competitive advantage over normal HSCs and the parental MDS clone, but even in combination fail to confer self-renewal potential to downstream progenitors. Even at diagnosis, MDS-SCs typically harbored multiple somatic mutations, including recurrent driver mutations, acquired in a linear, rather than branching, manner within the Lin
Sequencing analysis provided insights into the relationship between del(5q) and somatically acquired mutations, in particular in isolated del(5q) MDS. In more than 50% of isolated del(5q) cases, no recurrent driver mutation was identified by targeted or exome sequencing. Although our sequencing strategies may have missed recently identified recurrent mutations in MDS (Klampfl et al., 2013; Nangalia et al., 2013; Papaemmanuil et al., 2013) and additional significant mutations are likely to be identified in the future, this is unlikely to explain why the fraction of cases without identified recurrent driver mutations is higher in patients with isolated del(5q) than in other groups with low-to intermediate-risk MDS and del(5q) . In further support of del(5q) being the initiating genomic lesion in isolated del(5q) MDS, in all cases with at least one identifiable recurrent driver mutation where high confidence sequence of event prediction could be made, del(5q) preceded the acquired mutations. These findings, combined with our lack of evidence for a pre-MDS SC population, and the absence of deletions involving the 5q CDR in a large-scale screen for frequent copy number variations in the Figure S6 , and Tables S6 and S7. blood from older normal individuals (Jacobs et al., 2012) , are compatible with del(5q) being an initiating and potentially also the only genomic lesion required to develop the distinct clinical entity of isolated del(5q) MDS. However, further genomic analysis of patients and genetic modeling will be required to unequivocally establish if del(5q) is sufficient to induce isolated del(5q) MDS. Recent studies have shed some light on candidate genes within the 5q CDR responsible for causing some of the phenotypes associated with isolated del(5q) MDS (reviewed in Komrokji et al., 2013) . It will be important to explore to what degree haploinsufficiency of the same or distinct genes in the 5q CDR is responsible for the competitive advantage of del(5q) over normal HSCs.
The only low-to intermediate-risk cases in which del(5q) was not the first identified genomic lesion were four cases of ring sideroblastic anemia in which del(5q) was preceded by a recurrent SF3B1 mutation. Intriguingly, just as del(5q) might largely define the phenotype of isolated del(5q) MDS, SF3B1 mutations are thought to be an early and potentially initiating event defining ring sideroblastic anemia (Papaemmanuil et al., 2011; Yoshida et al., 2011) .
Although limited to four MDS cases with del(5q), tracking CD34 + CD38
À CD90 + MDS-SCs and progenitors by sequential genomic and functional analysis provided insights into the landscape of somatic mutations in stable disease and preceding disease progression, and how they might impact on the MDS stem and progenitor cell hierarchy. In two patients with del(5q) who remained transfusion-independent on long-term lenalidomide treatment, the majority of Lin
remained part of the del(5q) clone, and no mutations present at diagnosis had been eliminated, nor had any new been acquired. This suggests that in patients with low-risk del(5q) with stable disease, the landscape of somatic mutations in MDS-SCs may be quite stable. However, in two other patients with low-risk isolated del(5q) MDS who later transformed to AML, additional mutations were identified in the SC-compartment while BM blasts remained <5%. In both cases, a recurrent TP53 mutation emerged, conferring worse prognosis (Jä dersten et al., 2011) . When one of these patients progressed to RAEB-1 with a higher blast count, additional mutations were mapped to the MDS-SC compartment. However, a predicted passenger mutation (PIFO) could not be mapped to the SC compartment but was instead observed at a high frequency in expanded progenitor compartments along with the preceding TP53 mutation, Although possessing properties predicting that they will be challenging to target effectively (Tehranchi et al., 2010) , the identification of distinct and rare MDS-SCs will facilitate identification of molecular targets and development of targeted therapies to eliminate MDS-SCs in a disease currently notoriously difficult to cure. Although CSCs in more aggressive human cancers may not be rare, the distinct functional and molecular identity of MDS-SCs established here highlights the critical importance of continued efforts to identify in vivo, monitor and therapeutically target distinct CSCs, as their elimination should not only be essential but, in principle, also sufficient for development of curative cancer therapies.
EXPERIMENTAL PROCEDURES Patients
Patients with low-to intermediate-risk MDS were included (see Table S1 for clinical details). BM from age-matched healthy individuals was always used for controls unless otherwise specified. All patients provided written informed consent and the study was approved by the ethics committees at the Karolinska Institute, The Norwegian Radiumhospital, Aarhus University Hospital, University of Pavia, Hô pital Avicenne Assistance Publique-Hô pitaux de Paris (AP-HP), University of Dundee, St. James Hospital, University of Oxford, University of New South Wales and Skå ne University Hospital.
Flow Cytometry
Stem/progenitor analysis/isolation in BM mononuclear cells was performed as described (Tehranchi et al., 2010) and outlined in the Supplemental Experimental Procedures.
Gene Expression Analysis
Gene expression was analyzed by Fluidigm Dynamic Arrays and global RNA sequencing (Supplemental Experimental Procedures).
FISH
Interphase FISH for del(5q) and +8 was performed as described in the Supplemental Experimental Procedures.
In Vitro Assays
Detailed methods for colony-forming cell (CFC), long-term-culture-CFC (LTC-CFC), and B cell potential, as well as short-term expansion of single cells are described in the Supplemental Experimental Procedures. 
Xenograft Transplantation
DNA Mutational Analysis
Targeted sequencing and exome sequencing for detection, tracking and quantification of genetic lesions were performed and analyzed as described in the Supplemental Experimental Procedures. Briefly, mutations were identified in bulk MDS BM by targeted sequencing of coding region of genes recurrently mutated in myeloid malignancies using a HaloPlex kit (Agilent Technologies) or custom designed RNA baits (Papaemmanuil et al., 2013) , as well as by whole exome sequencing using a SureSelect kit (Agilent Technologies) according to the manufacturer's instructions. Mutations were back-tracked to stem and progenitor compartments by targeted sequencing, either using HaloPlex kit or Access Array chip (Fluidigm) with custom designed PCR primers.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 6 software. For individual comparisons nonparametric Mann-Whitney test was used and p values less than 0.05 were considered significant. Details of the bioinformatic analysis are included in the Supplemental Experimental Procedures.
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